DSDong Sun

Dong Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dong Sun has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment of infected lower limb bone defects using the bone transport with locking plate technique (BTLP): A retrospective case series of 90 patients

    by Xiaohua Wang, Shulin Wang, Feilong Yang, Feibo Wang, Jie Shen, Dong Sun, Guanglin Wang, Zhao Xie


  • Open Access

    Infographic: Chongqing technique

    by Jie Shen, Zhiyuan Wei, Dong Sun, Hongri Wu, Xiaohua Wang, Shulin Wang, Fei Luo, Zhao Xie

    Cite this article: Bone Joint Res 2024;13(3):124–126.


  • Open Access

    Accelerated osteogenesis of bone graft by optimizing the bone microenvironment formed by electrical signals dependent on driving micro vibration stimulation

    by Yuehao Wu, Jinjie Wu, Xu Huang, Xiupeng Zhu, Wei Zhi, Jianxin Wang, Dong Sun, Xuening Chen, Xiangdong Zhu, Xingdong Zhang


  • Open Access

    Incidence and risk factors of recurrence in limb osteomyelitis patients after antibiotic‐loaded cement spacer for definitive bone defect treatment

    by Hongri Wu, Dong Sun, Shulin Wang, Chao Jia, Jie Shen, Xiaohua Wang, Chunli Hou, Zhao Xie, Fei Luo

    Aims: This study was designed to characterize the recurrence incidence and risk factors of antibiotic-loaded cement spacer (ALCS) for definitive bone defect treatment in limb osteomyelitis.Methods: We included adult patients with limb osteomyelitis who received debridement and ALCS insertion into the bone defect as definitive management between 2013 and 2020 in our clinical centre. The follow-up time was at least two years. Data on patients’ demographics, clinical characteristics, and infection recurrence were retrospectively collected and analyzed.Results: In total, 314 patients with a mean age of 52.1 years (SD 12.1) were enrolled. After a mean of 50 months’ (24 to 96) follow-up, 53 (16.9%) patients had infection recurrence including 32 tibiae, ten femora, ten calcanea, and one humerus. Of all patients with recurrence, 30 (9.6%) occurred within one year and 39 (12.4%) within two years. Among them, 41 patients needed reoperation, five received antibiotics treatment only, and seven ultimately required amputations. Following multivariable analysis, we found that patients infected with Gram-negative bacilli were more likely to have a recurrence (odds ratio (OR) 2.38, 95% confidence interval (CI) 1.20 to 6.94; p = 0.046) compared to Staphylococcus aureus; segmental bone defects (OR 5.25, 95% CI 1.80 to 15.26; p = 0.002) and smoking (OR 3.00, 95% CI 1.39 to 6.50; p = 0.005) were also independent risk factors for recurrence after treatment.Conclusion: Permanent ALCS might be an alternative strategy for definitive bone defect management in selected osteomyelitis cases. However, the overall high recurrence found suggests that it should be cautiously treated. Additionally, segmental defects, Gram-negative infections, and smoking were associated with an increased risk of infection recurrence.Cite this article: Bone Joint Res 2023;12(8):467–475.


  • Open Access

    Roles of the Siglec family in bone and bone homeostasis

    by Zi Ye, Yetong Wang, Binqing Xiang, Heng Wang, Haiyan Tao, Chengmin Zhang, Shuai Zhang, Dong Sun, Fei Luo, Lei Song


  • Open Access

    Epidemiological updates of post-traumatic related limb osteomyelitis in china: a 10 years multicentre cohort study

    by YouLiang Ren, Lei Liu, Dong Sun, ZhengDong Zhang, Meng Li, Xu Lan, JiangDong Ni, Ming-Ming Yan, Wei Huang, Zi-Ming Liu, et al.

    Background: Post-traumatic related limb osteomyelitis (PTRLO) is a complex bone infection. Currently, there are no available microbial data on a national scale that can guide appropriate antibiotic selection, and explore the dynamic changes in dominant pathogens over time. This study aimed to conduct a comprehensive epidemiological analysis of PTRLO in China. Methods: The study was approved by the Institutional Research Board (IRB), and 3526 PTRLO patients were identified from 212 394 traumatic limb fracture patients at 21 hospitals between 1 January 2008 and 31 December 2017. A retrospective analysis was conducted to investigate the epidemiology of PTRLO, including changes in infection rate (IR), pathogens, infection risk factors and antibiotic resistance and sensitivity. Results: The IR of PTRLO increased gradually from 0.93 to 2.16% (Z=14.392, PP0.05). The most prevalent GP strains were Methicillin-sensitive Staphylococcus aureus (MSSA) (17.03%), Methicillin-resistant Staphylococcus aureus (MRSA) (10.46%), E. faecalis (5.19%) and S. epidermidis (4.87%). In contrast, the dominant strains GN strains were Pseudomonas Aeruginosa (10.92%), E. cloacae (10.34%), E. coli (9.47%), Acinetobacter Baumannii (7.92%) and Klebsiella Pneumoniae (3.33%). In general, the high-risk factors for polymicrobial infection include opened-fracture (odds ratio, 2.223), hypoproteinemia (odds ratio, 2.328), and multiple fractures (odds ratio, 1.465). It is important to note that the antibiotics resistance and sensitivity analysis of the pathogens may be influenced by complications or comorbidities. Conclusions: This study provides the latest data of PTRLO in China and offers trustworthy guidelines for clinical practice. (China Clinical Trials.gov number, ChiCTR1800017597).


  • Open Access

    Investigating clinical characteristics and prognostic factors in patients with chronic osteomyelitis of humerus

    by Hongri Wu, Shengpeng Yu, Jingshu Fu, Dong Sun, Shulin Wang, Zhao Xie, Yungui Wang

    Background: Chronic osteomyelitis in the humerus, which has complex neuroanatomy and a good soft tissue envelope, represents a unique clinical challenge. However, there are relatively few related studies in the literature. This article retrospectively reviewed a large case series with the aims of sharing our management experiences and further determining factors associated with the outcomes. Methods: Twenty-eight consecutive adult patients with a mean age of 36 years were identified by reviewing the osteomyelitis database of our clinic centre. The database was used to prospectively identify all osteomyelitis cases between 2013 and 2017, and all data then was retrospectively analysed. Results: The mean follow-up period was 35 months (range 24–60). The aetiology was trauma in 43% (12) of the patients and haematogenous in 57% (16) of the patients, and Staphylococcus aureus was a solitary agent in 50% (14) of the patients. Host-type (Cierny’s classification) was IA in 8, IIIB in 11 and IVB in 9 patients. All patients required debridement followed by the placement of a temporary antibiotic-impregnated cement spacer (rod). Seventeen patients received a cement-coated plate for internal fixation after debridement, and 13 patients needed bone grafts when the spacer was staged removed. All patients attained an infection-free bone healing state at the final follow-up. The final average DASH (disabilities of the arm, shoulder and hand) score was 18.14 ± 5.39, while 6 patients (two developed traumatic olecranarthritis, four developed radial nerve injuries) showed the lowest levels of limb function (p = 0.000) and were unemployed. Three patients (type I; significant difference between type I versus type III and type IV patients, p < 0.05) experienced recurrence after debridement and underwent a second revision, which was not related to the bone graft (p = 0.226) or plate fixation (p = 0.050). Conclusions: Humeral chronic osteomyelitis can be treated with general surgery and anti-infective therapy; medullary (type I) infection presents a challenge, and the antibiotic-coated cement plate provides favourable fixation without increasing recurrence of infections. Clinicians should be aware of potential iatrogenic nerve injuries when treating these patients with complicated cases, and an experienced surgeon may improve the outcome.


    • 1 January 2018
      • Vol. 10  (8) , 2737-2746

    1,25(OH)2D3 suppresses proinflammatory responses by inhibiting Th1 cell differentiation and cytokine production through the JAK/STAT pathway

    by Zehua Zhang, Feifan Chen, Jianhua Li, Fei Luo, Tianyong Hou, Jianzhong Xu, Dong Sun

    1,25(OH)(2)D-3 is an immune modulation hormone with beneficial effects on T cell- mediated autoimmune diseases. The purpose of the present study is to investigate the direct effects of vitamin D on Bacillus Calmette Guerin (BCG)-infected CD4+ T cells in both VDR-deficient (VDR-/-) mice and wild type (WT) mice. Specifically, we aimed to investigate the effect of vitamin D on Th1 cells and elucidate the underlying molecular mechanism. Naive CD4 T cells were purified from VDR-/- mice and WT mice to induce Th1 cells and were activated by BCG. Th1 cell differentiation and cytokine production in vitro were inhibited by 10 nM 1,25(OH)(2)D-3. The JAK/STAT pathway was activated by 1,25(OH)(2)D(3 )addition in both VDR-/- and wild type T cells. In vivo, a vitamin D-deficiency VDR-/- and WT mouse model was established and the mice were vaccinated with BCG. An ELISA assay was performed to measure the levels of VD, IL-2, IFN-gamma and TNF-beta in the blood, and flow cytometry was used to analyze the proportion of Th1 and Th2 cells in the spleen. 1,25(OH)(2)D(3 )affected Th cells polarization by inhibiting Th1 and augmenting Th2 cell development in the vitamin D-deficiency mouse model. Moreover, 1,25(OH)(2)D-3 inhibited the inflammatory infiltrates and expression of IL-2, IFN-gamma and TNF-beta in the spleen of vitamin D-deficient mice following vaccination with BCG. These findings suggested that 1,25(OH)(2)D(3 )suppressed the inflammatory response by inhibiting Th1 cell differentiation and cytokine production by the JAK/STAT pathway.


  • Open Access

    The outcomes of chemotherapy only treatment on mild spinal tuberculosis

    by Zehua Zhang, Fei Luo, Qiang Zhou, Fei Dai, Dong Sun, Jianzhong Xu

    The treatments for spinal tuberculosis (TB) patients without absolute surgical indications have been controversial. Some people believed that most spinal TB patients were indicated for surgery, while other people believed in chemotherapy only. To help clarify the treatment over spinal TB patients without absolute surgical indications, we characterized a subtype spinal TB and then analyzed the treatment outcomes of standard chemotherapy alone. In this retrospective study, 740 adult patients of spinal TB from January 2005 to January 2013 in our institution were reviewed. Patients who fit into the characterizations of mild spinal TB were started by standard chemotherapy for 18 months and followed up for at least 2 years upon the completion of treatment. The overall outcome, neurological function, local kyphosis, and level of pain at different time points were assessed. After starting the conservative treatment, 89 out of 740 patients were chosen for chemotherapy alone, and all patients were followed up for at least 2 years (ranging from 24 to 50 months) upon the completion of the treatment. Of 89 patients, 95.4 % of patients showed a definite and clinical response within 1 month after starting the treatment, 69 % of patients had excellent to good results, with no complications of the disease, and 77.5 % had asymptomatic local kyphosis with intact neurological function; solid bony fusion of adjacent segment was achieved in 88.8 % of patients. We believe that the mild spinal TB respond well to the standard chemotherapy, and the detailed description of mild TB would provide crucial guidance in determination of conservative treatment.